tradingkey.logo

MDxHealth SA

MDXH
查看詳細走勢圖
3.530USD
+0.130+3.82%
收盤 02/06, 16:00美東報價延遲15分鐘
174.73M總市值
虧損本益比TTM

MDxHealth SA

3.530
+0.130+3.82%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+3.82%

5天

+0.86%

1月

+7.95%

6月

+32.71%

今年開始到現在

-1.12%

1年

+90.81%

查看詳細走勢圖

TradingKey MDxHealth SA股票評分

單位: USD 更新時間: 2026-02-06

操作建議

MDxHealth SA當前公司基本面數據相對健康,最新ESG揭露屬於行業領先水平。增長潛力很大。當前估值低估,在生物技術與醫療研究行業排名91/392位。機構持股佔比非常高,近一月多位分析師給出公司評級為強力買入。最高目標價為7.04。中期看,股價處於下降通道。近一個月,市場表現較強,技術面和基本面綜合得分較高,較強的走勢獲得基本面和技術面的印證。目前股價在壓力位和支撐位之間,可以做區間波段操作。

MDxHealth SA評分

相關信息

行業排名
91 / 392
全市場排名
218 / 4521
所屬行業
生物技術與醫療研究

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
中性

MDxHealth SA亮點

亮點風險
MDxHealth SA is a Belgium-based healthcare company which provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The Company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, as well as prediction of response to a specific therapy. Its tests include ConfirmMDx for Prostate Cancer, SelectMDx for Prostate Cancer, PredictMDx for Glioblastoma and AssureMDx for Bladder Cancer. The Company's corporate operations are based in Herstal, Belgium, as well as Irvine, the United States, and its laboratory operations are based in Nijmegen, the Netherlands, as well as Irvine, the United States.
業績高增長
公司營業收入穩步增長,連續3年增長143.02%
業績增長期
公司處於發展階段,最新年度總收入90.05M美元
估值合理
公司最新PE估值-3.54,處於3年歷史合理位
機構減倉
最新機構持股22.89M股,環比減少5.52%
詹姆斯·西蒙斯持倉
明星投資者詹姆斯·西蒙斯持倉,最新持倉202.80K股
活躍度增加
近期活躍度增加,過去20天平均換手率0.58

分析師目標

基於 6 分析師
強力買入
評級
6.040
目標均價
+325.35%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

MDxHealth SA新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

MDxHealth SA簡介

MDxHealth SA is a Belgium-based healthcare company which provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The Company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, as well as prediction of response to a specific therapy. Its tests include ConfirmMDx for Prostate Cancer, SelectMDx for Prostate Cancer, PredictMDx for Glioblastoma and AssureMDx for Bladder Cancer. The Company's corporate operations are based in Herstal, Belgium, as well as Irvine, the United States, and its laboratory operations are based in Nijmegen, the Netherlands, as well as Irvine, the United States.
公司代碼MDXH
公司MDxHealth SA
CEOMr. Michael K. McGarrity
網址https://mdxhealth.com/
KeyAI